Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 8
- Registration Number
- NCT05578859
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6019
- Registration Number
- NCT05284747
- Locations
- 🇺🇸
John Muir Health and Cardiovascular Institute, Concord, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Northern Arizona Healthcare Corporation Cardiovascular Institute, Flagstaff, Arizona, United States
AMG 701 Expanded Access Program
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Amgen
- Registration Number
- NCT05256446
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 507
- Registration Number
- NCT05111626
- Locations
- 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT05032066
- Locations
- 🇿🇦
Dr. Ismail Abdullah Private Practice, Cape Town, Western Cape, South Africa
🇦🇷Instituto De Enfermedades Respiratorias E Investigacion Medica, Florencio Varela, Buenos Aires, Argentina
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Amgen
- Registration Number
- NCT04998747
A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 73
- Registration Number
- NCT04948099
- Locations
- 🇵🇱
ARS RHEUMATICA Sp. z o.o. REUMATIKA-Centrum Reumatologii NZOZ, Warsaw, Mazowieckie, Poland
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Altoona Clinical Research, Duncansville, Pennsylvania, United States
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT04887064
- Locations
- 🇺🇸
Pinnacle Clinical Research - San Antonio, San Antonio, Texas, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT04825678
- Locations
- 🇺🇸
Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT04740034
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸UCSF, San Francisco, California, United States